-+ 0.00%
-+ 0.00%
-+ 0.00%

First Tracks Biotherapeutics Q3 2026 net loss narrows 25% to $31.36 million

PUBT·11/03/2026 21:37:16
Listen to the news
First Tracks Biotherapeutics Q3 2026 net loss narrows 25% to $31.36 million
  • First Tracks Biotherapeutics’ third-quarter 2026 net loss narrowed 25% year-over-year to $31.36 million.
  • Research and development expenses fell 28% to $23.85 million, primarily due to lower development costs for rosnilimab and ANB032.
  • An October private placement raised $200 million in gross proceeds.
  • ANB033 demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms in a Phase 1b celiac disease cohort.
  • A late-stage celiac disease trial is planned for 2027, with mucosal-healing cohort results expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Tracks Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031615PRIMZONEFULLFEED9869442) on November 03, 2026, and is solely responsible for the information contained therein.